Quantcast

uniQure and Medison Sign Glybera Distribution Agreement for Israel

June 18, 2014

AMSTERDAM and PETACH TIKVA, Israel, June 18, 2014 /PRNewswire/ –

uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Medison Pharma Ltd.,
Israel’s leading international healthcare marketing group, today announced an exclusive
distribution agreement under which Medison will market Glybera(R), uniQure’s gene therapy
product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the
Palestinian Authority. Medison will also be responsible for obtaining regulatory approval
for Glybera in both territories. Financial terms of the agreement have not been disclosed.
Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening,
orphan metabolic disease that results in patients’ inability to process fat in the blood
after a meal.

“Glybera represents an exciting opportunity for Medison to continue its leadership in
offering new innovative treatments in Israel,” stated Meir Jakobsohn, Founder and CEO of
Medison.

“After carefully evaluating different commercialization strategies for Glybera in the
Israeli market, we have concluded that partnering Glybera allows us to optimize the value
of the asset as we continue to develop our pipeline,” said Jorn Aldag, Chief Executive
Officer. “Medison has a well-established and significant commercial organization in Israel
with a proven track record in successfully marketing specialty products. Through this
partnership Glybera will be available to LPLD patients in Israel and the Palestinian
Authority sooner than otherwise possible. uniQure remains focused on the advance of
Glybera toward the initiation of the regulatory process in the USA this year, as well as
the further development of our candidate gene therapies currently in the clinic.”

About Medison

Medison is Israel’s leading marketing group, representing innovative niche healthcare
solutions companies such as Biogen Idec, Amgen, Shire and Ipsen. Employing a comprehensive
approach to sales and service, Medison supplies and maintains long-standing relations with
HMOs (Health Maintenance Organizations), local medical centers and physicians. Backed by
three generations of experience in the healthcare industry since 1937, Medison is uniquely
qualified to provide the complete spectrum of integrated services for international
companies looking to enter or expand their presence in the Israeli and Romanian healthcare
markets.

About uniQure

uniQure is delivering on the promise of gene therapy through single treatments with
potentially curative results. We have developed a modular platform to rapidly bring new
disease-modifying therapies to patients with severe disorders. We are engaged in multiple
partnerships and have obtained regulatory approval of our lead product, Glybera, in the
European Union for a subset of patients with LPLD.

            For more information please contact
        Sharon Blum
        Goldfinger Communication
        +972-52-4588955
        sharon@goldfingercom.com

SOURCE Medison Pharma


Source: PR Newswire



comments powered by Disqus